NasdaqGM:ITRM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States.


Snowflake Analysis

Slightly overvalued with limited growth.

Share Price & News

How has Iterum Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ITRM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-11.9%

ITRM

0.2%

US Pharmaceuticals

0.5%

US Market


1 Year Return

-86.6%

ITRM

15.1%

US Pharmaceuticals

18.7%

US Market

Return vs Industry: ITRM underperformed the US Pharmaceuticals industry which returned 15.1% over the past year.

Return vs Market: ITRM underperformed the US Market which returned 18.7% over the past year.


Shareholder returns

ITRMIndustryMarket
7 Day-11.9%0.2%0.5%
30 Day-14.4%2.6%4.9%
90 Day-73.6%1.5%19.8%
1 Year-86.6%-86.6%18.1%15.1%21.2%18.7%
3 Yearn/a33.6%23.7%46.2%36.8%
5 Yearn/a38.8%23.1%85.3%65.1%

Price Volatility Vs. Market

How volatile is Iterum Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Iterum Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ITRM ($0.91) is trading below our estimate of fair value ($11.8)

Significantly Below Fair Value: ITRM is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ITRM is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: ITRM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ITRM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ITRM has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Iterum Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

47.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ITRM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ITRM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ITRM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ITRM's revenue (77.1% per year) is forecast to grow faster than the US market (9.5% per year).

High Growth Revenue: ITRM's revenue (77.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ITRM's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Iterum Therapeutics performed over the past 5 years?

-40.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ITRM is currently unprofitable.

Growing Profit Margin: ITRM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ITRM is unprofitable, and losses have increased over the past 5 years at a rate of 40.8% per year.

Accelerating Growth: Unable to compare ITRM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ITRM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.1%).


Return on Equity

High ROE: ITRM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Iterum Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ITRM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ITRM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ITRM has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ITRM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ITRM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ITRM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 38.6% each year


Next Steps

Dividend

What is Iterum Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ITRM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ITRM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ITRM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ITRM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ITRM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Corey Fishman (55 yo)

4.75yrs

Tenure

US$1,392,031

Compensation

Mr. Corey N. Fishman serves as Independent Director at BioSpecifics Technologies Corp. since April 9, 2020. Mr. Fishman has been the Chief Executive Officer of Iterum Therapeutics Ltd since November 2015 a ...


CEO Compensation Analysis

Compensation vs Market: Corey's total compensation ($USD1.39M) is above average for companies of similar size in the US market ($USD589.02K).

Compensation vs Earnings: Corey's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Corey Fishman
President4.75yrsUS$1.39m1.13%
$ 213.6k
Judith Matthews
Chief Financial Officer4.75yrsUS$565.09k0.26%
$ 50.0k
Michael Dunne
Chief Scientific Officer4.75yrsUS$883.11k0.70%
$ 131.7k
Benjamin Pe
Vice President of Operations5.58yrsno datano data
Tom Loughman
VP & CMC Headno datano datano data
Louise Barrett
Secretaryno datano datano data

4.8yrs

Average Tenure

55yo

Average Age

Experienced Management: ITRM's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Corey Fishman
President4.75yrsUS$1.39m1.13%
$ 213.6k
Brenton K. Ahrens
Independent Interim Chairman1.17yrsUS$122.50k0.029%
$ 5.5k
Patrick Heron
Independent Director4.75yrsUS$119.00k0.042%
$ 8.0k
Ronald Hunt
Independent Director4.75yrsUS$131.00k0.027%
$ 5.1k
Mohammed Shahzad Malik
Independent Director3.25yrsUS$125.00k0.053%
$ 10.0k
David Kelly
Independent Director4yrsUS$139.00k0.17%
$ 33.0k
Mark Chin
Independent Director3.25yrsUS$128.50k0.056%
$ 10.6k

4.0yrs

Average Tenure

55yo

Average Age

Experienced Board: ITRM's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 47.8%.


Top Shareholders

Company Information

Iterum Therapeutics plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Iterum Therapeutics plc
  • Ticker: ITRM
  • Exchange: NasdaqGM
  • Founded: 2015
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$18.903m
  • Shares outstanding: 21.24m
  • Website: https://www.iterumtx.com

Number of Employees


Location

  • Iterum Therapeutics plc
  • Harcourt Centre
  • Block 2, Floor 3
  • Dublin
  • Co. Dublin
  • 2
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ITRMNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDMay 2018

Biography

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulope ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/14 13:05
End of Day Share Price2020/08/13 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.